Navigation Links
Assured Pharmacy, Inc. Announces Extension of Issuer Tender Offer
Date:11/18/2013

PLANO, Texas, Nov, 18, 2013 /PRNewswire/ -- Assured Pharmacy, Inc. (OTCQB: APHY), today announced that it has extended the expiration of its previously announced tender offer to exchange 16% Senior Convertible Debentures (the "Eligible Debentures") and warrants to purchase common stock (the "Eligible Warrants"), (collectively the "Eligible Securities") for either:

Option #1: The issuance of restricted shares of common stock for the settlement of the balance of the Eligible Debenture, which shall consist of principle plus the currently outstanding unpaid interest as of September 30, 2013, at $0.60 per share with the issuance of new warrants to purchase common stock (the "New Warrants") at an exercise price of $0.60 per share for the first twelve (12) months following the closing date of the issuer tender offer (the "Tender Offer") and $0.75 thereafter for the remainder of the New Warrant's term, with such term to be an extension of the term of the Eligible Warrant by an additional three (3) years, or

Option #2: The issuance of amended and restated debentures (the "New Debentures") which include the principal balance plus all accrued and unpaid interest as of September 30, 2013 of the Eligible Debentures with a reduction of the interest rate from sixteen percent (16%) to ten percent (10%), the extension of the maturity date for an additional three (3) years past the Eligible Debenture's maturity date, reduction of the conversion price to $0.75 per share, and execution of a subordination agreement pursuant to which the Company will make no further payments to the debt holders until such time as the redemption of certain Series D Preferred Stock (to be designated) has been made in full ("Subordination Agreement") and the issuance of New Warrants, the expiration date of which shall be 3 years past the expiration date set forth in the Eligible Warrants and a reduction of the conversion price to $0.75 per share.

T
'/>"/>

SOURCE Assured Pharmacy, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Assured Pharmacy, Inc. Announces 16% Senior Convertible Debenture and Warrant Exchange Offer
2. Assured Pharmacy Hires Hayden IR
3. Assured Pharmacy - 2013 Shareholder Letter
4. PLZ Aeroscience Acquires Assured Packaging
5. ResearchMoz.us: Biotechnology Market By Application (Biopharmacy, Bioservices, Bioagri, Bioindustrial), By Technology (Fermentation, Tissue Regeneration, PCR, Nanobiotechnology, DNA Sequencing & Others) - Global Industry Analysis, Size, Share, Growt
6. PrimeMail, Prime Therapeutics mail-service pharmacy, receives URAC Reaccreditation
7. Salveo Specialty Pharmacy, Inc. Completes Additional Equity and Debt Financings and Acquisition of Mission Road Pharmacy
8. New York City Mayor Bloomberg and Health Commissioner Farley Receive Flu Shot at Duane Reade Pharmacy, Highlight Importance of Flu Preparedness
9. URAC sets standards for community pharmacy, advances dialogue about pharmacists as medication experts
10. Intrepid Investment Bankers LLC Advises A-Med Health Care in the Sale of its Specialty Pharmacy Assets to Modern HC Pharmacy, Inc., a portfolio company of Altamont Capital Partners
11. Valeant Pharmaceuticals Announces Pricing Of Private Offering Of Senior Notes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... BOSTON , Jan. 15, 2014 Tegra Medical is ... Mark King as its new Chief Executive Officer.  Mark ... in which he has overseen the company,s four facilities in ... and Costa Rica.  Mr. King joined Tegra Medical in 2012 ...
(Date:1/15/2014)... Jan. 15, 2014  According to Millennium Research Group ... intelligence, the United States ... markets will expand moderately through 2022, with embolization ... particular, increasing interest in drug-eluting beads (DEBs) and ...
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com announces that ... in its catalogue: ... Delivery Systems -- Focus on End Users ... STUDY OBJECTIVES A drug delivery ...
Breaking Medicine Technology:Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18
... Nov. 7, 2011 Inovio Pharmaceuticals, Inc. (NYSE AMEX: ... 30, 2011. Total revenue was $2.6 million and $8.2 ... compared to $1.3 million and $3.8 million for the same periods ... nine months ended September 30, 2011, were $9.0 million and $24.0 ...
... CHICAGO, Nov. 7, 2011 UCB today announced findings ... rates to Cimzia ® (certolizumab pegol) plus methotrexate ... effect on structural joint damage in patients with moderate ... responses were found by both RAPID3 (Routine Assessment of ...
Cached Medicine Technology:Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 2Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 3Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 4Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 5Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 6Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 7Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 8Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 9New RAPID 1 Post-Hoc Analysis Showed Early Response to Cimzia® (certolizumab pegol) at Week 12 was Predictive of Week 52 Response 2New RAPID 1 Post-Hoc Analysis Showed Early Response to Cimzia® (certolizumab pegol) at Week 12 was Predictive of Week 52 Response 3New RAPID 1 Post-Hoc Analysis Showed Early Response to Cimzia® (certolizumab pegol) at Week 12 was Predictive of Week 52 Response 4New RAPID 1 Post-Hoc Analysis Showed Early Response to Cimzia® (certolizumab pegol) at Week 12 was Predictive of Week 52 Response 5New RAPID 1 Post-Hoc Analysis Showed Early Response to Cimzia® (certolizumab pegol) at Week 12 was Predictive of Week 52 Response 6New RAPID 1 Post-Hoc Analysis Showed Early Response to Cimzia® (certolizumab pegol) at Week 12 was Predictive of Week 52 Response 7New RAPID 1 Post-Hoc Analysis Showed Early Response to Cimzia® (certolizumab pegol) at Week 12 was Predictive of Week 52 Response 8New RAPID 1 Post-Hoc Analysis Showed Early Response to Cimzia® (certolizumab pegol) at Week 12 was Predictive of Week 52 Response 9New RAPID 1 Post-Hoc Analysis Showed Early Response to Cimzia® (certolizumab pegol) at Week 12 was Predictive of Week 52 Response 10New RAPID 1 Post-Hoc Analysis Showed Early Response to Cimzia® (certolizumab pegol) at Week 12 was Predictive of Week 52 Response 11New RAPID 1 Post-Hoc Analysis Showed Early Response to Cimzia® (certolizumab pegol) at Week 12 was Predictive of Week 52 Response 12
(Date:4/24/2014)... On April 28, the Center for BrainHealth will ... our most pressing brain-related challenges at its inaugural ... Resilience and Regeneration." Featured speakers will include Dr. ... the Center for BrainHealth, U.S. Senator Chuck Grassley ... Doggett, Deputy Assistant Secretary for Policy and Early ...
(Date:4/24/2014)... Depression affects more than one out of three ... study released in The Lancet Respiratory Medicine ... symptoms physically rather than mentally. , It is ... mental health and functional outcomes of critical care ... assistant professor of Medicine, and it highlights a ...
(Date:4/24/2014)... LA The National Science Foundation has awarded ... Experiences for Undergraduates (REU) Site grant in the ... training of undergraduates from diverse social and educational ... New Orleans area. The project will provide ... summers of 2014-16. It will be led ...
(Date:4/23/2014)... immigrants from Sub-Saharan Africa, Latin America and Caribbean ... to new research from St. Michael,s Hospital. , ... Journal of Obstetrics and Gynaecology , assessed the ... and native-born women in six high-immigration countries ... and Valencia) and the United States (California, New ...
(Date:4/23/2014)... 23, 2014 The American Society for Radiation Oncology ... of Postoperative Radiation Therapy for Endometrial Cancer: An ... adjuvant radiation therapy in the treatment of endometrial ... the May-June 2014 issue of Practical Radiation ... of ASTRO. The full-length guideline is available as ...
Breaking Medicine News(10 mins):Health News:Inaugural Brain Health Summit focuses on brain resilience and regeneration 2Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 2Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 3Health News:Pregnancy complications may be more common in immigrants from certain regions 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 3
... use a new combination of the chemotherapy, Capecitabine, together ... have an 88 percent chance of surviving the cancer ... at the plenary session, October 3, 2011, at the ... Oncology (ASTRO). "The results of the trial allow ...
... released this week, challenges people to test their knowledge ... they learn about the complexities of the disease, which ... Californians. Developed as a free download by the ... and QuantiaMD, a company headquartered in Waltham, Massachusetts, the ...
... The University of North Carolina at Chapel Hill has ... Institute of Diabetes and Digestive and Kidney Diseases to ... Reduce Health Disparities (CDTR). Its mission is to reduce ... resources and support to foster translational research in North ...
... from Rhode Island Hospital researchers suggests that controlling cholesterol may ... non-steroidal anti-inflammatory drugs (NSAIDs) such as naproxen. The findings are ... in clinically relevant animal models when high cholesterol is a ... the journal Surgery . NSAIDs are among ...
... health challenges earlier than their fellow seniors, researchers ... lives of 8,700 older people, a Case Western ... reported physical limitations by African American women in ... finding surfaced as researchers looked generally at how ...
... the Witwatersrand goldfields, not far from bustling Johannesburg, South Africa, ... littered with mounds of waste and underlain by a deep ... with water. Today, the mines are producing less and less ... estimate the volume of acid mine drainage from abandoned mines ...
Cached Medicine News:Health News:Chemo plus radiation before surgery increases tumor response for rectal cancer 2Health News:Interactive mobile app from UCSF and QuantiaMD teaches people how to manage diabetes 2Health News:Interactive mobile app from UCSF and QuantiaMD teaches people how to manage diabetes 3Health News:New UNC Center for Diabetes seeks to reduce health disparities 2Health News:New UNC Center for Diabetes seeks to reduce health disparities 3Health News:Rhode Island Hospital researchers find possible cardiovascular risk with NSAID use 2Health News:African-American women develop functional challenges earlier than others 2Health News:African-American women develop functional challenges earlier than others 3
Inquire...
... a premium agarose used for isolating DNA ... produces clear sharp bands, with no smearing ... UltraClean Forensic Agarose is tested and certified ... activity and DNA contamination. Meets ...
... 1000 is specifically formulated for high resolution ... <1000 bp. This standard melting temperature agarose ... as 10 bp difference in size. ... gel structure for better handling and improved ...
Excellent multi purpose agarose Nuclease-free, Gel point (1.5%): 36 1.5 C, EEO: 0.05-0.13 Gel strength (1%): > 1200 g/cm 2 ....
Medicine Products: